CYP19A1 and breast cancer: The first line of estrogen receptor (ER)-positive breast cancer treatment in the clinic is endocrine therapy, where aromatase inhibitors (AIs) and antiestrogen drugs, respectively, block estrogen formation and ER activity [196].